Traditionally, men undergoing a regular biopsy will undergo an ultrasound-guided biopsy without the help of a previous MRI. This entails using the ultrasound probe to target multiple areas of the prostate using a 12-zone pattern. If there are abnormal areas in those zones, those will be targeted at that time with the ultrasound. The small specimens are then sent to the pathologist to be evaluated for cancer. People referred to these as “random” biopsies, but they are not truly random as they target specific zones of the prostate. Unfortunately, the ultrasound has limitations and many cancers can be missed with ultrasound guidance alone.
A fusion biopsy incorporates the MRI that has already been completed prior to the patient coming to the clinic. The MRI images are then fused with the live ultrasound images, and a “fused image” is made. This is only possible if an abnormal lesion is found on the MRI. Assuming a lesion is found on the MRI, the fused image is created, and the lesion is marked and targeted in a more precise fashion to evaluate whether the abnormal MRI lesion is cancerous. This can be tricky and depends on the quality of the MRI as well as ensuring the two images have fused together correctly. Dr. Rich Bevan-Thomas has one of the highest experience rates with the technology, dating back to 2012. He currently uses the inVivo and Dynacad platform by Philips.